News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH COVID-19 VACCINE (BNT162b2) IN HIGH-RISK INDIVIDUALS

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The objective of the study is to determine the effectiveness of a 3rd dose and/or 4th Dose in the prevention of SARS-CoV-2 infections and determine the anti-SARS-CoV-2 IgG antibody titers using a semi quantitative 2. method at various time points (Baseline/Day0, Day14, Week12 and Week 24 after booster)

Information: 

Principal Investigator
Sohail Rao, MD
Sponsor
DHR Health Institute for Research and Development
Type of Trial
Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram